Evotec SE (NASDAQ:EVO – Get Free Report)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $3.64, but opened at $3.54. Evotec shares last traded at $3.55, with a volume of 4,948 shares changing hands.
Evotec Stock Down 2.5 %
The business’s 50-day moving average price is $4.16 and its two-hundred day moving average price is $4.09. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.
Hedge Funds Weigh In On Evotec
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP increased its position in Evotec by 29.7% during the third quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock worth $9,616,000 after purchasing an additional 602,858 shares during the last quarter. DCF Advisers LLC grew its stake in Evotec by 5.9% during the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company’s stock worth $956,000 after buying an additional 12,816 shares during the period. Lighthouse Investment Partners LLC purchased a new stake in Evotec during the fourth quarter worth approximately $166,000. Bank of America Corp DE grew its stake in Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares during the period. Finally, CSS LLC IL purchased a new stake in Evotec during the fourth quarter worth approximately $50,000. Institutional investors and hedge funds own 5.81% of the company’s stock.
Evotec Company Profile
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.
Recommended Stories
- Five stocks we like better than Evotec
- 3 Healthcare Dividend Stocks to Buy
- 4 Undervalued Growth Stocks to Buy and Hold for the Long Term
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Why Are These Companies Considered Blue Chips?
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.